Drug
Avalglucosidase alfa clinical trials
Also written GZ402666.
- studies test it
- 9
- open now
- 1
- in phase 3
- 2
- first study started
- 2001
Keep track of what changes. Save the avalglucosidase alfa studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
Development codes
Other names
Combined with it in one product
Studies by the year they started
9 studies that test it; most in 2022 (2)
| Year | Studies |
|---|---|
| 2001 | 1 |
| 2011 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2016 | 1 |
| 2021 | 1 |
| 2022 | 2 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 3
- Phase 3
- 2
- Phase 4
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 8 · Other 1
Genzyme, a Sanofi Company (6) · Iris Plug (1) · Sanofi (1) · Amicus Therapeutics (1)
Often tested with
Tested in the same studies.
Duvoglustat (1) · Alglucosidase alfa (1)
Studies
Open first, then newest update. How each study uses avalglucosidase alfa is read from its arms, and is right about nine times in ten.
Testing it · 9
- China Post-approval Commitment (PAC) Study of Avalglucosidase Alfa in Participants With IOPDRecruitingPhase 4Genzyme, a Sanofi CompanyNCT06666413Written as Avalglucosidase alfa
- Avalglucosidase Alfa French Post-trial Access for Participants With Pompe Disease (PTA Avalglucosidase)Active, not recruitingPhase 4Genzyme, a Sanofi CompanyNCT05164055Written as Avalglucosidase alfa (GZ402666)
- Safety and Efficacy of Avalglucosidase Alfa in Patients With Non-classic Pompe Disease Aged ≥ 5 YearsActive, not recruitingPhase 4Iris PlugNCT07652814Written as Avalglucosidase Alfa
- Clinical Study for Treatment-naïve IOPD Babies to Evaluate Efficacy and Safety of ERT With Avalglucosidase AlfaActive, not recruitingPhase 3SanofiNCT04910776Written as avalglucosidase alfa
- Drug-drug Interaction StudyCompletedPhase 2Amicus TherapeuticsNCT01380743Written as rhGAA
- Study to Compare the Efficacy and Safety of Enzyme Replacement Therapies Avalglucosidase Alfa and Alglucosidase Alfa Administered Every Other Week in Patients With Late-onset Pompe Disease Who Have Not Been Previously Treated for Pompe DiseaseCompletedPhase 3Genzyme, a Sanofi CompanyNCT02782741Written as Avalglucosidase alfa (GZ402666)
- Avalglucosidase Alfa Extension StudyCompletedPhase 2Genzyme, a Sanofi CompanyNCT02032524Written as Avalglucosidase Alfa
- Safety and Efficacy Evaluation of Repeat neoGAA Dosing in Late Onset Pompe Disease Patients.CompletedPhase 1Genzyme, a Sanofi CompanyNCT01898364Written as GZ402666
- Safety and Efficacy of Recombinant Human Acid Alpha-Glucosidase in the Treatment of Classical Infantile Pompe DiseaseCompletedPhase 2Genzyme, a Sanofi CompanyNCT00025896Written as recombinant human acid alpha-glucosidase (rhGAA)
Given in every arm · 1 — avalglucosidase alfa is usual care beside what is tested
As the comparator · 1 — what is tested is compared with avalglucosidase alfa
Codes
What other systems call avalglucosidase alfa · ClinicalTrials.gg INT002184
- MeSH (NLM) C000731975avalglucosidase alfaOne source NLM
- UNII (FDA) EO144CP0X9AVALGLUCOSIDASE ALFAConfirmed FDA, NLM, Wikidata
- RxNorm 2565814One source FDA
- Wikidata Q107693067avalglucosidase alfaConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C169795Avalglucosidase AlfaOne source FDA
- DrugBank DB16099One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000731975 | avalglucosidase alfa | One source NLM |
| UNII (FDA) | EO144CP0X9 | AVALGLUCOSIDASE ALFA | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2565814 | — | One source FDA |
| Wikidata | Q107693067 | avalglucosidase alfa | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C169795 | Avalglucosidase Alfa | One source FDA |
| DrugBank | DB16099 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.